U.S. Consumer Durables Stock News

Fidelity National Information Services (FIS) just delivered an earnings beat, raised its full year revenue and EBITDA guidance, and boosted its share buyback plans, a combination that usually forces investors to revisit the stock. See our latest analysis for Fidelity National Information Services. Even with the upbeat guidance and larger buyback, sentiment is still resetting. The share price is $65.17 and the year to date share price return is negative 18.63 percent, reinforcing a longer term...

Organon (OGN) has been quietly grinding through a rough stretch, with the share price slipping over the past month and past 3 months, so investors are asking whether the downside now reflects opportunity. See our latest analysis for Organon. With the share price now at $6.95 and a steep year to date share price return decline, sentiment clearly shifted. However, the three year total shareholder return slide suggests this has been a long, grinding de rating rather than a sudden shock. If...

Concentra Group Holdings Parent recently opened Concentra Corona, a new occupational health medical center at 629 North Main Street, Unit C-3, Corona, California, offering work injury care, physical therapy, drug testing, DOT physicals, pre-placement exams, and employer-focused telemedicine services. This expansion deepens Concentra’s California footprint and highlights how its proprietary Concentra Telemed platform is being integrated alongside brick‑and‑mortar clinics to support employer...

If you are wondering whether Alphatec Holdings at around $20.67 is still a smart buy after its huge run, or if the easy money has already been made, you are not alone. The stock has slipped 2.6% over the last week but is still up 2.1% over 30 days, with an eye catching 128.1% gain year to date and 113.3% over the past year. This naturally raises questions about how much upside is left. Investors have been reacting to a stream of positive updates around Alphatec's expanding spine surgery...

In early December 2025, BioNTech and its partners OncoC4 and Bristol Myers Squibb reported past trial data showing that their experimental cancer therapies gotistobart and pumitamig improved outcomes versus standard care in difficult-to-treat lung and triple-negative breast cancers, with manageable safety profiles and ongoing Phase 3 programs. These oncology readouts suggest BioNTech’s pipeline is starting to yield clinically meaningful assets in high-need solid tumors, potentially...

Frontline plc’s 2025 Annual General Meeting on 8 December 2025 approved Richard C. Prince as a new director and backed wide share issuance authority, following the US$290 million sale of its five oldest VLCCs and fleet growth to 84 vessels after acquiring 24 VLCCs from Euronav. This combination of board refresh and large-scale asset rotation highlights Frontline’s move toward a younger, more flexible tanker fleet that could influence capital allocation choices. Next, we’ll explore how...

Wondering if Abercrombie & Fitch is still a bargain after its big run, or if the easy money has already been made? You are not alone; this stock has been firmly on value hunters' radars. Despite slipping about 0.2% over the last week, the share price has surged roughly 39.7% in the past month. Longer term returns are mixed, with a 332.5% gain over 3 years but a 27.7% drop over the last year. Recently, the market has been reacting to Abercrombie & Fitch's ongoing brand reinvention and...

If you have been wondering whether Popular is still a buy after its big multi year run, you are not alone. This article will walk through what the current share price is really baking in. The stock has slipped about 0.6% over the last week but remains up 1.0% over the past month, with a strong 25.7% gain year to date and a hefty 142.7% return over five years that suggests the market has steadily been repricing its prospects. Recent headlines have focused on Popular's positioning in Puerto...

If you have been wondering whether Concentrix is a beaten down bargain or a value trap, you are not alone. This article will walk through the numbers in plain English. The stock has bounced recently, up 3.2% over the last week and 10.4% over the past month, even though it is still down 12.5% year to date and 11.3% over the last year. Over a longer horizon, it has seen a much steeper 67.8% slide over three years and 59.0% over five. That kind of whiplash performance has been shaped by...

Wondering if Antero Midstream is still a good buy after its run up, or if most of the easy money has already been made? In this article, we break down what the market is really pricing in here. The stock has climbed to around $18.58, delivering roughly 4.6% over the last week, 4.9% over the past month, 20.0% year to date and 30.5% over the last year, with a 109.6% gain over three years and 235.0% over five years. Those moves have come as midstream energy names like Antero have benefited from...

Wondering if SLM is quietly trading below what it is really worth? You are not alone. This stock has been catching the eye of investors hunting for mispriced financial names. Despite a choppy ride in the short term, with the share price down 12.8% over the last week and 4.1% year to date, the longer term story still shows gains of 68.1% over 3 years and 138.6% over 5 years. Recent market moves have come as investors reassess student loan and consumer credit exposure in a higher rate...

CNH Industrial (NYSE:CNH) is back in focus after two fresh partnership moves, pairing with CHC Navigation on high precision guidance kits and deepening its Cyient alliance around autonomous construction systems. See our latest analysis for CNH Industrial. Those autonomy and precision upgrades come against a tougher market backdrop, with a 90 day share price return of minus 16.7 percent and a one year total shareholder return of minus 20.9 percent, suggesting sentiment has weakened even as CNH...

Clover Health Investments recently reported winning new contracts, supported by an average 10.3% increase in its customer base over the past two years. Earnings per share have compounded at a very large annual rate while cash burn has steadily reduced, pointing to improving operational self-sufficiency. Now we’ll explore how these contract wins and improving earnings quality might reshape Clover Health’s existing technology-focused investment narrative. Trump has pledged to "unleash"...

Apellis Pharmaceuticals (APLS) has quietly staged a rebound this month, with the stock up roughly 23% even as its past year performance remains weak, inviting a closer look at what might be changing. See our latest analysis for Apellis Pharmaceuticals. The 23.5% 1 month share price return has helped Apellis claw back some ground from a difficult stretch. However, the 1 year total shareholder return remains deep in negative territory, which suggests sentiment may be stabilising rather than...

If you are wondering whether UMB Financial is quietly trading at a discount or already priced for perfection, you are not alone. This stock has been drawing attention from investors hunting for value in regional banks. Despite some short-term noise, the share price is up 3.4% over the last month and 1.9% year to date, though it is still down 7.5% over the past year after a strong multiyear climb of 50.8% over three years and 79.4% over five years. Recent headlines around the regional banking...

In recent days, Solid Power disclosed that director Erik Anderson sold 30,000 shares and the company amended its Executive Change in Control and Severance Plan, reshaping how senior leaders could be compensated if control changes occur. These governance moves, coming alongside continued discussion of losses and negative cash flow despite high-profile partnerships and government backing, spotlight the tension between Solid Power’s technological promise and its financial strain. Next, we’ll...

If you are wondering whether O'Reilly Automotive is still attractive after its long run higher, or if the easy money has already been made, you are not alone. This breakdown is designed to cut through the noise and focus on what the stock may really be worth. Even after a recent pullback of about 4.4% over the last week and 3.9% over the last month, the stock is still up 19.0% year to date and 11.4% over the past year. That caps off a multi year climb of 73.6% in three years and 210.7% in...

While M/I Homes, Inc. ( NYSE:MHO ) shareholders are probably generally happy, the stock hasn't had particularly good...

In early December 2025, Flywire Corporation announced a partnership with TenPay Global to add Weixin Pay (WeChat Pay) for Chinese students paying tuition to universities in South Korea and Malaysia, aiming to simplify cross-border education payments for families. This move gives Flywire more direct access to fast-growing intra-Asia student flows, where Chinese enrollment in Malaysia and South Korea has risen sharply since 2019, reinforcing its position in international education payments...

If you are wondering whether PVH is starting to look like a bargain after a rough stretch or if it is cheap for a reason, you are not alone. This is exactly the kind of setup where valuation work really matters. The stock has slipped to around $76.12 after a 13.1% drop over the last week and is now down 27.4% year to date and 30.5% over the last year, shifting many investors from growth optimism to value hunting mode. Recent market chatter has focused on how PVH is navigating a tougher...

If you are wondering whether Arch Capital Group at around $91.92 is still a smart buy or if most of the upside is already priced in, you are not alone. That is exactly what we are about to unpack. Despite a modest 0.6% gain year to date and a 1.5% slide over the last year, the stock is still sitting on returns of 61.4% over 3 years and 176.7% over 5 years, indicating that long-term holders have already been well rewarded. Recent headlines have focused on Arch Capital Group expanding its...

Galaxy Digital’s recent acquisition of staking software firm Alluvial Finance made it the Development Company for Liquid Collective, giving it full responsibility for building and maintaining one of the leading institutional liquid staking protocols, which has grown assets on platform to about US$1.00 billion since launch. This move tightens Galaxy’s grip on institutional onchain infrastructure, complementing its growing AI-optimized data center ambitions and broadening its role across both...

Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...

Ingersoll Rand (NYSE:IR) has had a rough three months with its share price down 3.3%. However, the company's...